Tempus
Tempus Labs, Inc. (commonly known as Tempus or Tempus AI, Inc. following its IPO) is a precision medicine and technology company focused on using artificial intelligence and data analytics to personalize cancer care and other areas of medicine. The company builds and operates a large-scale library of clinical and molecular data and provides decision-support tools to physicians and researchers.
AI Strategy
Tempus focuses on aggregating and structuring vast amounts of clinical, molecular, and imaging data, then applying machine learning models to generate insights that can guide diagnosis, treatment selection, and drug development. Its strategy centers on being an infrastructure and analytics layer for precision medicine, partnering with health systems, life sciences companies, and researchers to embed AI-driven decision support into clinical workflows.
Key AI Products
Financials
Funding
Business Focus
Competitive Analysis
Strengths
- •Large and growing library of clinical and molecular data
- •Deep specialization in oncology and precision medicine
- •Integrated platform combining lab services, data infrastructure, and AI analytics
- •Strong relationships with health systems and life sciences companies
Challenges
- •Highly regulated healthcare and data privacy environment
- •Competition from well-funded healthcare data and diagnostics players
- •Dependence on continued data access and partnerships with providers
- •Complex and lengthy enterprise sales cycles in healthcare
Strategic Partnerships
Tempus partners with large health systems and academic medical centers to ingest de-identified clinical and molecular data and deploy its AI-driven decision-support tools within clinical workflows.
Tempus collaborates with life sciences companies to support drug discovery, clinical trial design, and patient matching using its data platform and AI models.